Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Veritas Pharma Inc (OTC: VRTHF).

Full DD Report for VRTHF

You must become a subscriber to view this report.


Recent News from (OTC: VRTHF)

Veritas inks marketing deal with ExtractionTek Solutions
Veritas Pharma ( OTCPK:VRTHF ) announces that subsidiary 3 Carbon Extractions has completed an exclusive marketing arrangement with ExtractionTek Solutions, a maker of closed loop hydrocarbon extraction equipment. More news on: Veritas Pharma Inc, Consumer stocks news, Healthcare stocks ...
Source: SeekingAlpha
Date: September, 05 2018 16:28
Veritas Welcomes Exclusive Marketing Agreement Between 3 Carbon Extractions and ExtractionTek Solutions
VANCOUVER, British Columbia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”)  is pleased to announce that its subsidiary, 3 Carbon Extractions Inc. ( “3 CARBON” ), ...
Source: GlobeNewswire
Date: September, 05 2018 16:10
Veritas Appoints Lorne Mark Roseborough CEO of SunVault Energy to the Board of Directors
VANCOUVER, British Columbia, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce the appointment of Lorne Mark Roseborough as a Director of the Company. L...
Source: GlobeNewswire
Date: September, 04 2018 19:00
5 of Today's Biggest Marijuana Stock Losers - Tuesday, September 4th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Tuesday, September 4th including India Globalization Capital, Inc. (NYSE:IGC) and more… Affinor Growers Inc. (CSE:AFI) (OTC:RSSFF) Shares of Affinor Growers Inc. dropped 8.90% o...
Source: Daily Marijuana Observer
Date: September, 04 2018 18:28
Veritas Completes Share Purchase Agreement with 3 Carbon Extractions Inc.
VANCOUVER, British Columbia, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that the Company has completed the Share Purchase Agreement ( “Purchas...
Source: GlobeNewswire
Date: August, 27 2018 16:58
5 of Today's Biggest Marijuana Stock Losers - Friday, August 17th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Friday, August 17th including Axim Biotechnologies, Inc. (OTC:AXIM) and more... Axim Biotechnologies, Inc. (OTC:AXIM) Shares of Axim Biotechnologies, Inc. dropped 6.07% today on higher...
Source: Daily Marijuana Observer
Date: August, 17 2018 17:28
5 of Today's Biggest Marijuana Stock Losers - Thursday, August 16th
Out of over 200+ marijuana stocks, here are just 5 of the biggest marijuana stock losers in trading on Thursday, August 16th including General Cannabis Corp. (OTC:CANN) and more... Alternate Health Corp. (CSE:AHG) (TSX:AHGIF) Shares of Alternate Health Corp. dropped 10.66% today on high...
Source: Daily Marijuana Observer
Date: August, 16 2018 18:51
Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited
VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding ( “MOU” ) with...
Source: GlobeNewswire
Date: August, 15 2018 16:05
Veritas Signs MOU with the Chamber of Commerce, Industry, Services and Tourism Brazil & Puerto Rico
VANCOUVER, British Columbia, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company) is pleased to announce that it has entered into a Memorandum of Understanding ( “MOU” ) with t...
Source: GlobeNewswire
Date: August, 13 2018 09:00
Frankfurt's Clearstream Banking Lifts Settlement Restrictions on Securities Active in Medical Cannabis
VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that Clearstream Banking, a major central securities depository based in Fran...
Source: GlobeNewswire
Date: August, 08 2018 03:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.09370.0890.09620.084453,875
2018-12-120.0820.09110.09120.080546,925
2018-12-110.08840.08750.08840.0839,390
2018-12-100.088650.09170.09170.08248557,024
2018-12-070.096040.09520.10360.088519,457

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1341,40053,87576.8445Short
2018-12-121,00046,9252.1311Cover
2018-12-1128,60939,39072.6301Short
2018-12-1023,76057,02441.6667Short
2018-12-061,00011,3798.7881Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRTHF.


About Veritas Pharma Inc (OTC: VRTHF)

Logo for Veritas Pharma Inc (OTC: VRTHF)

The medical marijuana industry is projected to have substantial growth over the next few years and Veritas is among the first to employ a comprehensive scientific approach behind medical marijuana claims. Our mission is to develop the most effective proprietary cannabis strains for specific disease conditions providing doctors and patients with conclusive scientific evidence for the recommendation and use of medical marijuana with confidence. Veritas has formed an exclusive partnership and investment in Cannevert Therapeutics, a high level research and development company, with its main office on the University of British Columbia UBC campus. Cannevert has brought together a highly accredited team of pharmacologists, anaesthetists and chemists with proven track records of success in drug development in both academia and industry. This alliance will provide Veritas with the required technical ability to achieve its goals in research, development and commercialization.

 

Contact Information

 

 

Current Management

  • Lui Franciosi / CEO
    • Dr. Franciosi has more than years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange AIM: VRP . Prior to Verona Pharma, Dr. Franciosi completed his postdoctoral research in COPD progression modeling at the Clinical Pharmacology amp Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate amp Masters degrees at The University of British Columbia UBC , Canada and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology amp Therapeutics.
  • David Alexander / CFO
    • Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include his role as the CFO of Arakis Energy Corporation, an international oil and gas development company, where he managed the company s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company Nasdaq: CRME .
  • David Alexander / Director
    • Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include his role as the CFO of Arakis Energy Corporation, an international oil and gas development company, where he managed the company s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company Nasdaq: CRME .
  • Donald R. Carlow / Director
    • Dr. Carlow was the past President and CEO Jan Oct of the British Columbia Cancer Agency BCCA . Dr. Carlow s efforts led to the development of new cancer centers, as well as laying the groundwork for the BC Cancer Research Center. Dr. Carlow was a member of the board of the Vancouver Island Health Authority, where he chaired the board s health quality committee for four years. He proposed the establishment of the BC Council on Quality and Safety. Additionally, he acted as a judge for the M National Health Care Quality Awards for four years during the s.
  • Lui Franciosi / Director
    • Dr. Franciosi has more than years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange AIM: VRP . Prior to Verona Pharma, Dr. Franciosi completed his postdoctoral research in COPD progression modeling at the Clinical Pharmacology amp Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate amp Masters degrees at The University of British Columbia UBC , Canada and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology amp Therapeutics.
  • Yari Nieken / Director
    • Mr. Nieken has a wide range of public company and capital market experience. He is Founder and President of Foremost Capital Inc. an Exempt Market Dealer. He is also a public company consultant with Paradigm Shift Consulting. He has served on the boards of several public and private issuers andhas raised substantial capital in his career. He holds an MBA from the Sydney Graduate School of Management and a BA from the University of British Columbia. He was formerly an investment advisor at Union Securities Corp. and continues to be a registrant in good standing in the provinces of British Columbia, Alberta, and Ontario.
  • Linda Sampson /

Current Share Structure

  • Market Cap: $16,538,873 - 03/16/2018
  • Issue and Outstanding: 38,714,590 - 12/06/2017

 



Daily Technical Chart for (OTC: VRTHF)

Daily Technical Chart for (OTC: VRTHF)


Stay tuned for daily updates and more on (OTC: VRTHF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: VRTHF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRTHF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRTHF and does not buy, sell, or trade any shares of VRTHF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/